Search

Your search keyword '"Yeh B"' showing total 239 results
Start Over Author "Yeh B"
239 results on '"Yeh B"'

1. Ugonin J Acts as a SARS-CoV-2 3C-like Protease Inhibitor and Exhibits Anti-inflammatory Properties

Author

Wei-Chung Chiou, Hsu-Feng Lu, Nung-Yu Hsu, Tein-Yao Chang, Yuan-Fan Chin, Ping-Cheng Liu, Jir-Mehng Lo, Yeh B Wu, Jinn-Moon Yang, and Cheng Huang

Subjects
3CL protease inhibitor, ugonin J, COVID-19, SARS-CoV-2, lung inflammation, Therapeutics. Pharmacology, RM1-950
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes severe “flu-like” symptoms that can progress to acute respiratory distress syndrome (ARDS), pneumonia, renal failure, and death. From the therapeutic perspective, 3-chymotrypsin-like protein (3CLpro) is a plausible target for direct-acting antiviral agents because of its indispensable role in viral replication. The flavonoid ugonin J (UJ) has been reported to have antioxidative and anti-inflammatory activities. However, the potential of UJ as an antiviral agent remains unexplored. In this study, we investigated the therapeutic activity of UJ against SARS-CoV-2 infection. Importantly, UJ has a distinct inhibitory activity against SARS-CoV-2 3CLpro, compared to luteolin, kaempferol, and isokaempferide. Specifically, UJ blocks the active site of SARS-CoV-2 3CLpro by forming hydrogen bonding and van der Waals interactions with H163, M165 and E166, G143 and C145, Q189, and P168 in subsites S1, S1′, S2, and S4, respectively. In addition, UJ forms strong, stable interactions with core pharmacophore anchors of SARS-CoV-2 3CLpro in a computational model. UJ shows consistent anti-inflammatory activity in inflamed human alveolar basal epithelial A549 cells. Furthermore, UJ has a 50% cytotoxic concentration (CC50) and a 50% effective concentration (EC50) values of about 783 and 2.38 µM, respectively, with a selectivity index (SI) value of 329, in SARS-CoV-2-infected Vero E6 cells. Taken together, UJ is a direct-acting antiviral that obstructs the activity of a fundamental protease of SARS-CoV-2, offering the therapeutic potential for SARS-CoV-2 infection.

Published
2021
Full Text
View/download PDF

2. Alleviating Effects of Ovatodiolide and Antcin K Supplements on High-Fat Diet-Induced Cardiovascular Dysfunction in ApoE-Knockout Mice by Attenuating Oxidative Stress

Author

Chen-Wen Lu, Wen-Jhen Wu, Thi Kim Ngan Nguyen, Szu-Chuan Shen, Yeh-B. Wu, Hui-Ju Liang, and Chung-Hsin Wu

Subjects
hyperlipidemia, atherosclerosis, cocktail therapy, oxidative stress, inflammation, high-fat diet, Nutrition. Foods and food supply, TX341-641
Abstract

A high-fat diet (HFD) is a major risk factor for cardiovascular diseases. Many pure compounds have been demonstrated to be effective in treating cardiovascular diseases. In this study, we investigated the alleviating effects of oral ovatodiolide and antcin K (OAK) supplements on HFD-induced cardiovascular dysfunction in apolipoprotein E (ApoE)-knockout mice. Cardiovascular dysfunction was induced in ApoE-knockout mice by feeding them an HFD for 12 weeks. The degree of cardiovascular dysfunction was assessed through echocardiography, hematological and biochemical analyses, and immunofluorescence and immunohistochemical staining. The HFD-fed mice exhibited cardiovascular dysfunction—abnormal blood biochemical index. The arterial wall tissue exhibited the marked deposition of lipids, upregulated expression of vascular cell adhesion molecule-1 and CD36 receptors, and downregulated expression of the ABCA1 receptor. Macrophages isolated from the peritoneal cavity of the mice exhibited increased levels of lipid accumulation, reactive oxygen species, and CD11b expression but reduced mitochondrial membrane potential. The expression of superoxide dismutase 2 was downregulated and that of tumor necrosis factor-α was upregulated in the myocardial tissue. Oral OAK supplements twice a day for 12 weeks significantly mitigated HFD-induced cardiovascular dysfunction in the experimental mice. Oral OAK supplements appear to be a promising strategy for treating HFD-induced cardiovascular dysfunction. The underlying mechanisms may involve the reduction of lipid accumulation in the artery and oxidative stress and inflammation in the cardiovascular tissue.

Published
2023
Full Text
View/download PDF

19. P0093 AMACR overexpression is associated with clinical and biological aggressiveness in urothelial carcinomas of the upper urinary tract and urinary bladder

Author

Li, C.-F., primary, Wu, W.-J., additional, Huang, C.-N., additional, Li, C.-C., additional, Ke, H.-L., additional, Li, W.-M., additional, Yeh, H.-C., additional, Lee, Y.-Y., additional, Lin, H.-H., additional, Yeh, B.-W., additional, Hwang, S.-J., additional, and Liang, P.-I., additional

Published
2014
Full Text
View/download PDF

22. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer

Author

Kelley, R K, primary, Hwang, J, additional, Magbanua, M J M, additional, Watt, L, additional, Beumer, J H, additional, Christner, S M, additional, Baruchel, S, additional, Wu, B, additional, Fong, L, additional, Yeh, B M, additional, Moore, A P, additional, Ko, A H, additional, Korn, W M, additional, Rajpal, S, additional, Park, J W, additional, Tempero, M A, additional, Venook, A P, additional, and Bergsland, E K, additional

Published
2013
Full Text
View/download PDF

34. 1059

Author

Dai, C.Y., primary, Yeh, B., additional, Lessard, E., additional, Joe, B.N., additional, Pouliot, J., additional, and Hsu, I.J., additional

Published
2006
Full Text
View/download PDF

37. Change in circulating endothelial cells (CEC) and tumor cells (CTC) in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC) predicts stable disease at first evaluation

Author

Rugo, H. S., primary, Dickler, M. N., additional, Scott, J. H., additional, Moore, D. H., additional, Melisko, M., additional, Yeh, B. M., additional, Caravelli, J., additional, Brogi, E., additional, Hudis, C., additional, and Park, J. W., additional

Published
2005
Full Text
View/download PDF

38. A feasibility study of an aromatase inhibitor (AI), letrozole (L) and the antibody to vascular endothelial growth factor (VEGF), bevacizumab (B), in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)

Author

Traina, T. A., primary, Dickler, M. N., additional, Caravelli, J. F., additional, Yeh, B. M., additional, Brogi, E., additional, Panageas, K., additional, Flores, S. A., additional, Norton, L., additional, Hudis, C., additional, and Rugo, H., additional

Published
2005
Full Text
View/download PDF

44. The effectiveness of corticosteroids in the treatment of sore throat: a systematic review of controlled clinical trials

Author

Wing, A., Villa-Roel, C., Yeh, B., Eskin, B., Buckingham, J., and Rowe, B.H.

Subjects
Corticosteroids, Pharyngitis, Clinical trials, Health, Health care industry, Science and technology
Abstract

Introduction: Sore throat is a common emergency department (ED) symptom; most cases are self-limiting viral infections. Despite this, physicians prescribe antibiotics and corticosteroids (CS) to reduce patient (pt) symptoms. This systematic review examined the effectiveness of systemic CS for relief of acute sore throat symptoms. Methods: Cochrane, MEDLINE, EMBASE, Scopus and BIOSIS Previews electronic searches (ES); conference proceedings and clinical trials databases (CT), and Web of Science (WS) searches were performed. Only randomised controlled trials in which CS (alone or in combination with regular abortive therapy) were compared to placebo for treatment of acute sore throat in adults or children were included; mononucleosis studies were excluded. Relevance, inclusion, and study quality were assessed independently by 2 reviewers. Weighted mean differences (WMD) are reported with 95% confidence intervals (CI). Results: Searches identified 73 ES, 235 CT and 21 WS potentially relevant citations; 8 studies involving 849 pts met the inclusion criteria. Studies were published between 1993 and 2005, had high quality scores, and 3 exclusively recruited children. Half of the included trials reported on Group A Beta-Hemolytic Streptococci (GABHS) subgroups; all studies provided antibiotics. Most treatments compared single-dose CS to placebo; various oral and IM CS doses were administered. CS improved pain at 24 (WMD = -1.35; 95% CI -2.1to -0.6) and 48 (-0.98; 95% CI -1.52 to -0.4) h; results for 24 h were heterogeneous (I2 > 85%). CS reduced time to clinically significant pain relief (-2.86 h; 95% CI -3.6 to -2.12); results were heterogeneous (I2 > 91%). Heterogeneity was not explained by the GABHS status. Side effect profiles were similar between CS and placebo groups. Conclusion: The use of CS in the treatment of sore throat demonstrates heterogeneity. Despite this, there appears to be a small benefit associated with this treatment. Research is required to determine which subgroups benefit most. Keywords: corticosteroids, pharyngitis, systematic review

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results